The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C10 | Lipid modifying agents | |
| 3 | C10A | Lipid modifying agents, plain | |
| 4 | C10AB | Fibrates | |
| 5 | C10AB05 | Fenofibrate |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.2 g |
| Active Ingredient | Description | |
|---|---|---|
| Fenofibrate |
Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans are mediated via activation of Peroxisome Proliferator Activated Receptor type α (PPARα). Through activation of PPARα, fenofibrate increases lipolysis and elimination of atherogenic triglyceride rich particles from plasma by activating lipoprotein lipase and reducing production of Apoprotein C-III. |
|
| Fenofibric acid |
|
| Title | Information Source | Document Type | |
|---|---|---|---|
| LIPANTHYL Penta Film-coated tablet | Health Sciences Authority (SG) | MPI, Generic | |
| LIPANTIL Capsule | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| LIPIDIL NT Film coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| TRICOR Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
